Statements (35)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
quetiapine fumarate
|
| gptkbp:approvalYear |
2007
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
N05AH04
|
| gptkbp:brand |
quetiapine fumarate extended-release
|
| gptkbp:contraindication |
hypersensitivity to quetiapine
|
| gptkbp:drugClass |
antipsychotic medication
|
| gptkbp:eliminatedIn |
urine and feces
|
| gptkbp:firstApprovedCountry |
gptkb:United_States
|
| gptkbp:form |
50 mg
extended-release tablet 150 mg 200 mg 300 mg 400 mg |
| gptkbp:genericAvailable |
yes
|
| gptkbp:halfLife |
about 7 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Seroquel XR
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:AstraZeneca
|
| gptkbp:metabolism |
liver (CYP3A4)
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:orthostatic_hypotension
constipation dizziness weight gain drowsiness dry mouth |
| gptkbp:usedFor |
bipolar disorder
schizophrenia major depressive disorder (adjunct) |
| gptkbp:bfsParent |
gptkb:quetiapine
|
| gptkbp:bfsLayer |
6
|